Hi ItsaYes, Biogen ended up 38% yesterday based on the FDA's...

Hi Itsa

Yes, Biogen ended up 38% yesterday based on the FDA's incorrect decision to allow its Alzheimer's drug to market - just a gain of US$17 BILLION in market cap.

This illustrates just how huge the market is for successful drugs - in this case, for a drug that supposedly will offer benefit to 6 million people in the US suffering from the disease, so it's targeting a major market, with no competition. But it doesn't work!

Yesterday's article in Bloomberg provides a good summary: https://www.bloomberg.com/opinion/articles/2021-06-07/approving-biogen-s-alzheimer-s-drug-aducanumab-aduhelm-is-big-mistake "Biogen's drug (which it will market under the brand name Aduhelm at a hefty price of about $56,000 a year) cuts plaque, but the resulting patient benefit in even the positive trial is so modest that it may not be significant. Many other medicines have targeted amyloid. Unfortunately, all failed to help patients, leading scientists to question whether removing the plaque does anything."

Perhaps, as we've speculated, removing inflammation from the brain with ATL 1102 will be more beneficial. But the Bloomberg article suggests that the faulty FDA decision may make alternative therapies more difficult to gain acceptance. We hope that the storm of protests convinces the FDA to take a different position.